

NOVEL STATISTICAL METHODS

Doubly Robust Estimation of Causal Effect

Upping the Odds of Getting the Right Answers

ABSTRACT: Propensity score–based methods or multiple regressions of the outcome are often used for confounding adjustment in analysis of observational studies. In either approach, a model is needed: A model describing the relationship between the treatment assignment and covariates in the propensity score–based method or a model for the outcome and covariates in the multiple regressions. The 2 models are usually unknown to the investigators and must be estimated. The correct model specification, therefore, is essential for the validity of the final causal estimate. We describe in this article a doubly robust estimator which combines both models propitiously to offer analysts 2 chances for obtaining a valid causal estimate and demonstrate its use through a data set from the Lindner Center Study.

Xiaochun Li, PhD
Changyu Shen, PhD

BACKGROUND

Observational data is a rich source for investigation of exposure effects, for example, in the research of comparative effectiveness and safety of treatments. Exposure effects or causal effects can be formulated in terms of potential outcomes in Rubin's causal model framework.¹ Given a choice of 2 exposures (mutually exclusive for a certain time interval), a patient has a pair of potential outcomes, one outcome for each exposure. In actuality, a patient is assigned to only one exposure, and thus only one potential outcome is observed. Suppose we could rewind the time machine and have the patient experience the other exposure and observe the outcome, the causal effect for this patient can be defined as some contrast (eg, absolute difference) between the 2 potential outcomes under respective exposures, and the average causal effect (ACE) is the average of differences of the 2 potential outcomes across all patients in a relevant population. Because we can only observe one potential outcome in reality, patient-level causal effect is not directly estimable. Thus, it is usually the ACE that is the target of most studies. In fact, ACE can also be defined without the conceptual involvement of patient-level causal-effect. For example, risk differences, ACEs for binary outcomes can be risk ratios or odds ratios.

Randomization in clinical trials is a tool that enables the estimation of ACE through randomly creating exposure groups, both of which are representative of the entire population with the only difference being the treatment assignment. However, although randomization is useful in ensuring exchangeability of treatment groups, the ACE on the efficacy of an intervention can only be estimated when the randomized trial is perfectly executed, with perfect adherence to assigned treatment, no protocol deviations, perfect data capture, and no loss of patients to

Key Words: health status ■ odds ratio
■ propensity score ■ research
■ risk

© 2019 American Heart Association, Inc.

<https://www.ahajournals.org/journal/circoutcomes>

follow-up and so on. In contrast, the treatment assignments in observational studies are not randomized and often depend on patients' characteristics (confounding by indication), simple group comparisons tend to lead to biased causal estimates. For example, physicians make treatment decisions based on patients' demographics and pretreatment health status that are associated with the outcomes, rendering differences in outcomes between treatment groups not exclusively attributable to the causal effect of the treatment on the outcomes. Therefore, factors affecting the treatment assignment and associated with the outcome need to be accounted for to remove the confounding bias in the analysis to produce valid causal estimate. In causal inference, the most essential assumption for unbiased estimation of a treatment effect is that we have at our disposal all variables (X) that are associated with both the treatment and the outcome (namely, confounders; this assumption is known as the assumption of no unmeasured confounders). Various statistical methods have been developed to adjust for confounding to enable valid comparisons, among which multivariable regression models of the outcome and propensity-score based approaches are often used in applications.²⁻⁶ Notably, the topic of propensity-score based methods as well as their implementations is the focus of an earlier article⁵ in the series of Primer on Statistical Methods of this journal.

In this report, we describe 2 common but contrasting approaches to causal effect estimation: multivariable regressions that focus on outcome modeling and inverse probability weighting using propensity score that focuses on exposure modeling. We discuss the common challenges to both, and then introduce their fortuitous combination—the doubly robust (DR) estimator. Using a public data set from the Lindner Center Study, we demonstrate the steps of DR estimation to assess the effect of the treatment of abciximab on patients' 6-month mortality and the cardiac-related costs incurred within 6 months of patients' initial percutaneous coronary intervention (PCI).

Multivariable Outcome Regressions

The most common approach to causal estimation is the prediction of potential outcomes for every subject via the use of the classic multivariable outcome regression models—for example, linear, logistic, Cox PH models, and so on—in which an outcome is modeled in terms of the exposure variable and a set of baseline covariates, which should include variables associated with both the exposure and the outcome (confounders) and preferably variables related to the outcome only (prognostic factors). The confounders are necessary for reducing bias in the causal estimate and improving its precision; the prognostic factors are primarily for further enhancement in the precision of the estimate.

We will focus on the 2 common outcomes, continuous and binary. Estimating the marginal ACE requires marginalization. Specifically, the estimated outcome regression model is used to produce a pair of predicted potential outcome values for each subject using this subject's baseline covariates, one for each exposure. The marginal mean of each potential outcome can be estimated by taking the average across all subjects. The ACE can then be constructed based on the specific metric of interest by using the 2 estimated marginal means, be it the treatment difference, the risk difference, the risk ratio, or the odds ratio. The marginalization process is the same if 2 models are used for a continuous outcome with one model for each exposure group.⁷ The outcome regression estimator is consistent for ACE provided that there are no unmeasured confounders (all is, all relevant confounders are available and included in the analysis), and the relationship between the outcome and the treatment and a host of covariates is specified correctly in the multivariable model for the outcome.

Inverse Probability Weighting Using the Propensity Score

The propensity score (PS) of an exposure (or treatment) for a subject is defined as the conditional probability of receiving the exposure given the values of the baseline confounders of the subject. The PS is a one-dimensional representation of the multi-dimensional (even high-dimensional in some cases) baseline confounders. The fact that subjects with the same PS share a common distribution of the baseline confounders (included in the PS model) across exposure groups enables researchers to control for confounding through the use of the PS so as to derive causal estimate with minimal bias. The PS adjustment is especially useful when the conventional approach of a multivariable regression to simultaneously control many confounders is not feasible because of the rarity of the outcome. The PS can be used in the analyses in a variety of ways: PS matching, PS stratification, inverse probability weighting by PS (IPTW), or PS as a covariate in an outcome regression.⁵ These PS approaches are equivalent (Appendix B in the [Data Supplement](#)) subject to the validity of 3 assumptions: (1) there are no unmeasured confounders, (2) the PS is strictly greater than zero and less than one, and (3) models are correctly specified in respective PS approach. In practice, PS matching is often used to estimate the average treatment effect for the treated (ATT) rather than ACE. The approach of IPTW is to weight each subject with the inverse of the subject's PS or 1-PS: each subject with confounder values X in a treatment group is assigned a weight of 1/PS indicating that there are 1/PS subjects in the population with confounder values X; and each subject with confounders X in a control group

is assigned a weight of $1/(1-PS)$ for similar reasons.⁸ The consequence of such a weighting scheme is that the weighted groups are similar in confounders (ie, having the same distribution of the confounders) and thus comparable. Any differences in the distribution of the outcomes between the weighted groups can then be attributed to the treatment, after the differences in the confounders being accounted for by PS weighting. The ACE can then be estimated using the weighted outcomes from the 2 groups.

Model Estimation of Outcome Regression and PS

Regardless of which approach researchers take to estimate the ACE, a model is needed: an outcome regression model in the approach of modeling the outcome or a PS model in the approach of modeling the exposure. Assuming no uncontrolled confounders, the validity of the final causal estimates is contingent on the validity of respective models. To build a model in general, we need to decide what independent variables should be included and how these variables are related to the dependent variable. Hence, either the PS model or the outcome regression model should include X . In addition, it is shown^{9,10} that there may be further gains in efficiency to include in either models the covariates V that are not related to treatment exposure but are associated with potential response. Therefore, all confounders X and all covariates that are prognostic should be included provided the sample size allows for reliable estimation of the model.

Model checking and diagnostics for either models should follow the standard practice. Furthermore, for propensity-based methods in general, the PS distributions should be examined for overlap. In the case of substantial nonoverlap, researchers may want to restrict their estimation task to the overlap and as a consequence clarify the appropriate inferential population to which the causal estimate resulting from the subsample is applicable.

THE DOUBLY ROBUST ESTIMATOR

The DR estimator we discuss in this article is a propitious combination of the IPTW and outcome regression, which is a consistent estimator (ie, verging to be unbiased as sample size tends toward infinity) if either the PS model or the outcome regression model is correctly specified and is the most efficient if both are correct.¹¹ The idea behind this estimator is proposed by Robins et al¹¹ to improve the IPTW by augmenting it with the prognostic information in the confounders. When the PS model is correct, the expectation of the IPTW term is the causal effect, and the expectation of the second term is zero because of the expectation of

the weighted residuals of the PS model is zero, even if the outcome regression model is wrong; when the outcome regression model is correct, the expectation of both terms combined yields the causal effect, even if the PS model is wrong. Of course, when both the PS and the outcome regression models are correct, the DR estimator estimates the causal effect of interest, whereas when both are wrong, the DR estimator does not necessarily estimate the causal effect. Nonetheless, the DR estimator does offer us 2 opportunities to get a valid estimate of the causal effects through the specifications of the PS and outcome regression models. Since the DR estimator we present here is an extension of the IPTW, it is also called augmented IPTW method.⁵

Implementation

The implementation of the DR estimator for ACE in terms of marginal differences in potential outcomes is straightforward as depicted in the flowchart in Figure 1:

1. Estimate the PS model and obtain the predicted probability $\hat{\pi}_i$ for every subject in the entire sample.
2. Estimate the outcome regression models, one for each treatment group. Once the models are estimated, obtain the predicted values for the entire sample using each estimated model. The predicted values \hat{Y}_{i1} from the model estimated based on the exposed group are the counterfactual outcomes had all subjects been exposed; likewise, the predicted values \hat{Y}_{i0} from the model estimated based on the nonexposed group are the counterfactual outcomes had all subjects not been exposed.
3. Calculate the DR causal estimate $\hat{\Delta}_{DR}$ (Appendix in the [Data Supplement](#)).

If one is interested in obtaining ACE in terms of the risk ratio or the odds ratio for a binary outcome, one can obtain the marginal means of the potential outcomes—the 2 terms as separated by the minus sign in Step 3—and calculate the risk ratio or the odds ratio.

The DR estimator as described above is implemented in a SAS macro¹² developed at the University of North Carolina at Chapel Hill, where the macro and a sample data set are available for download. The macro is suited to the scenario of a dichotomous treatment variable and either a dichotomous or a continuous outcome variable. The authors demonstrated in the manual through the sample data set that DR estimates are consistent as long as one of 2 models, PS or outcome regression, is specified correctly. The authors include in their manual examples with a binary and a continuous outcome.

In the next section, we will analyze one real-life data example using SAS, a popular platform for statistical




Figure 1. Flowchart of steps of a doubly robust analysis.

PS indicates propensity score.

analysis. SAS's new procedure (as of November 2016) causaltrt offers all 3 estimators, outcome regression, IPTW, and DR.

APPLICATION TO THE LINDNER DATA

The Lindner Center Study

The Lindner Center Study is an observational study to evaluate the impact of adjunctive pharmacotherapy with abciximab platelet GP IIb/IIIa blockade during PCI on costs and clinical outcomes in a high-volume interventional practice, Ohio Heart Health Center of The Christ Hospital, in 1997.¹³ Confounding bias exists as the treatment was not assigned by randomization. In the original publication, PS stratification method was used to adjust for confounding bias. The average reduction in mortality rate at 6 months after abciximab therapy increases from the crude 3.4% to 4.9% after the PS stratification adjustment, and no substantially higher cost is found associated with the treatment. However, due to the issues of data privacy and confidentiality, only a subset of the study data is included in the R package USPS¹⁴ for public use. This data set will be used in this article to illustrate the DR approach to estimate the average treatment effect of abciximab on both the mortality and the cost.

The data set in the R package USPS consists of observations on 996 patients who were followed for at least 6 months after receiving an initial PCI. Among them, 698 of them received the treatment with the abciximab platelet GP IIb/IIIa blockade during PCI, and the remaining 298 patients received usual care alone while undergoing their PCI. For each patient, we have data on 10 variables described in Table 1.

The variable lifepres assumes only 2 distinct values, 0 if died within 6 months or 11.6 years otherwise. We define the 6-month mortality status mort as a binary variable, 1 if died within 6 months and 0 otherwise.

Mean baseline characteristics by whether they were treated with abciximab (1) or not (0) are summarized in the unweighted portion of Table 2. The unadjusted mortality rates were 5% for patients treated with the usual care and 2% for those treated with abciximab; the unadjusted average costs were \$14612.22 and \$16126.68 for those treated with the usual care and those treated with abciximab, respectively.

From this simple summary, the 2 groups of patients do not appear to be readily comparable. The abciximab-treated patients seem to be in worse pretreatment cardiac-related conditions than the usual-care patients. For example, the number of patients who had acute myocardial infarction before PCI is 2× more in the abciximab-treated cohort than in the usual-care cohort. If we look at the outcomes, abciximab-treated cohort has a 6-month mortality rate 3% lower than the usual-care cohort, but with about \$1500 more cost. An

Table 1. List of Variables in the Lindner Center Data

| Variable Name | Definition |
|---------------|--|
| Lifepres | Mean life years preserved due to survival for at least 6 mo after PCI |
| Cardbill | Cardiac-related costs incurred within 6 mo of patient's initial PCI |
| Abcix | Treatment indicator: 1 for abciximab and 0 for usual-care-alone |
| Stent | Coronary stent deployment: 1 for yes and 0 for no |
| Height | Height in centimeters |
| Female | Gender indicator: 1 for female and 0 for male |
| Diabetic | Diagnosis of diabetes mellitus: 1 for yes and 0 for no |
| Acutemi | Acute myocardial infarction within the 7 days before PCI: 1 for yes and 0 for no |
| Ejecfrac | The left ventricular ejection fraction |
| Ves1proc | Number of vessels involved in the patient's initial PCI |

PCI indicates percutaneous coronary intervention.

Table 2. Mean, SD, and Standardized Difference Between Groups, Unweighted and Weighted


| Variable | Control Group | | Abcixib Group | | Standardized Diff (%) |
|------------|---------------|------|---------------|------|-----------------------|
| | Mean | SD | Mean | SD | |
| Unweighted | | | | | |
| Stent | 0.58 | 0.49 | 0.70 | 0.46 | 25 |
| Height | 171 | 11 | 171 | 11 | 0.034 |
| Female | 0.39 | 0.49 | 0.33 | 0.47 | 11 |
| Diabetic | 0.27 | 0.44 | 0.20 | 0.40 | 15 |
| Acutemi | 0.06 | 0.24 | 0.18 | 0.38 | 37 |
| Ejecfrac | 52 | 10 | 50 | 10 | 18 |
| Ves1proc | 1.2 | 0.48 | 1.5 | 0.71 | 43 |
| Weighted | | | | | |
| Stent | 0.67 | 0.47 | 0.67 | 0.47 | 0.63 |
| Height | 171 | 12 | 171 | 11 | 1.1 |
| Female | 0.33 | 0.47 | 0.34 | 0.48 | 2.2 |
| Diabetic | 0.24 | 0.43 | 0.22 | 0.42 | 5.2 |
| Acutemi | 0.14 | 0.35 | 0.14 | 0.35 | 0.29 |
| Ejecfrac | 51 | 10 | 51 | 10 | 0.049 |
| Ves1proc | 1.4 | 0.7 | 1.4 | 0.66 | 6.5 |

interesting question is whether the treatment is cost-effective, after adjusting for the confounding factors. In the following sections, we will demonstrate our analysis using this data set.

Analysis

We begin by estimating the PS by using logistic regression with main effects of all the seven covariates in Table 2. The distributions of estimated PS for the 2 groups, abciximab treated and not treated, are displayed in Figure 2, where we see that the 2 distributions appear to overlap quite well. We will examine the balance of covariates in the 2 groups by summarizing the unweighted and the PS-weighted standardized differences for the 7 covariates in Table 2, following the recommendations^{15,16} of best practice. By Cochran's 0.25 rule, if the standardized difference of a variable exceeds 0.25, the variable is imbalanced between the 2 groups. The unweighted standardized differences of variables stent, acutemi, and ves1proc as shown in Table 2 exceed 0.25, and thus those 3 variables are imbalanced between the treated and the untreated groups. In contrast, after inverse weighting by propensity score, the standardized differences of all 7 covariates are well within 0.25 (Table 2). This indicates the appropriateness of the PS model, in addition to the Hosmer-Lemeshow test ($P=0.37$) of the goodness of the model fit.

Next we fit 2 logistic models for the mortality outcome, one for the abciximab treatment group and one for the nontreated group. Then we use each model,

**Figure 2.** Distribution of logit of propensity score for the 2 groups, one treated with abciximab (abcix=1) and the other not (abcix=0).

in turn, to predict the counterfactual responses for all patients in the sample—now each patient has 2 predicted probabilities of mortality if he or she was treated by abciximab and if he or she was not treated. We can now employ the formulae (Appendix A in the [Data Supplement](#)) to compute the ACE on mortality and its SE. For the cost outcome, we follow the same steps, except that we fit 2 linear regression models instead because this outcome is continuous.

Thanks to a SAS's new procedure, proc causaltrt as released in SAS/STAT 14.2, all the above steps are packaged in a compact and user-friendly procedure. We used the procedure to obtain the DR estimates for both outcomes of the 6-month mortality and the cost in Table 3, with standard errors by the robust sandwich formula and alternatively by bootstrapping 1000 times. For comparison, we also display the results from the IPTW and the outcome regression approach.

From Table 3, we see that all 3 estimators yield essentially the same results: treatment with abciximab afforded survival advantage by at least 5% while maintaining similar cost to the nonabciximab treated group. For both outcomes, the outcome regression estimator has the smallest SE, and the IPW estimator has the largest SE.

The SAS code for this analysis is included in the Appendix C in the [Data Supplement](#).

DISCUSSION

In this article, we describe a DR estimator that combines 2 causal estimators advantageously, the IPTW and the outcome regression, to offer us 2 chances to obtain a consistent causal estimate of a treatment effect. As

Table 3. Estimates for Outcomes of 6-Month Mortality and Cost

| Method | Outcome | μ_0 | μ_1 | ACE | Robust SE | Bootstrap SE | Wald 95% CI | Bootstrap Bias Corrected 95% CI |
|--------|-----------|---------|---------|--------|-----------|--------------|-------------------|---------------------------------|
| DR | Mortality | 0.082 | 0.015 | −0.066 | 0.025 | 0.026 | −0.115 to −0.018 | −0.119 to −0.016 |
| | Cost | 15744 | 15995 | 251.46 | 1128.8 | 1110.4 | −1961.0 to 2464.0 | −2205.7 to 2146.7 |
| IPTW | Mortality | 0.082 | 0.015 | −0.067 | 0.029 | 0.031 | −0.123 to −0.011 | −0.144 to −0.018 |
| | Cost | 16009 | 15981 | −27.85 | 1292.0 | 1396.1 | −2560.2 to 2504.5 | −3598.2 to 2222.8 |
| REG | Mortality | 0.068 | 0.015 | −0.054 | 0.020 | 0.021 | −0.093 to −0.014 | −0.097 to −0.014 |
| | Cost | 15056 | 16037 | 981.6 | 906.2 | 915.1 | −794.5 to 2756.7 | −1040.5 to 2570.3 |

μ_0 , μ_1 are the averages of counterfactuals; ACE is the treatment effect. The Wald 95% CI is based on the robust SE. ACE indicates average causal effect; DR, doubly robust; IPTW, inverse probability treatment weighting; and REG, outcomes regression.

long as we specify one of the 2 models correctly, the causal estimate is valid (in the sense that its bias diminishes as sample size increases). One can afford to get one of the 2 models wrong and still obtain asymptotically unbiased causal estimate, which is certainly more advantageous in terms of robustness in estimation to a single model approach as in either IPTW or outcome regression. We outline the steps for the computation of the DR estimator and its SE, with the relevant formulae in the appendix in the [Data Supplement](#). We demonstrate the DR estimation process in contrast with IPTW and outcome regression through a real-life data set using a recently released SAS procedure causaltrt. From the results, we observe that although we arrive at the same conclusion by all 3 estimators, the estimators exhibit different variability. As a matter of fact, these estimators have the following behaviors in large samples. If both the PS model and the outcome regression model are specified correctly, the DR estimator has the smallest variance among all consistent estimators that involve inverse weighting; if the PS is modeled correctly, the DR estimator will have smaller variance than the simple inverse weighted estimator; if the outcome regression is modeled correctly, the DR estimator will likely have larger variance than the regression estimator.⁹ The implication of the above theoretical results is that when sample sizes are small, the inversed weighted estimators, IPTW and DR, may not have the precision needed for inference because the associated CIs are wide. In contrast, outcome regression estimators have narrower CIs, but they may be centered on the biased estimates if the outcome regression models are wrong. When sample sizes are large, bias becomes the upmost concern, DR is perhaps the best estimator among the 3 because it offers some protection against model-misspecification while IPTW and outcome regression do not. Finally, if both the PS and the outcome models are wrong, then DR estimator does not estimate the causal effect of interest and will give a wrong answer. However, if a non-DR estimator (IPTW or outcome regression) uses a wrong model, it also will not estimate the cause effect of interest, and the resulting estimate is wrong. DR estimators afford protection against model

misspecification by offering 2 chances at getting right answers (consistent estimates).

ARTICLE INFORMATION

The Data Supplement is available at <https://www.ahajournals.org/doi/suppl/10.1161/CIRCOUTCOMES.119.006065>.

Correspondence

Xiaochun Li, PhD, Department of Biostatistics, School of Medicine & Richard M. Fairbanks School of Public Health, Indiana University, 410 W 10th St, Suite 3000, Indianapolis, IN 46202. Email xiaochun@iu.edu

Affiliations

Department of Biostatistics, Indiana University School of Medicine, IN (X.L.). Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (C.S.).

Disclosures

None.

REFERENCES

1. Sekhon J. The Neyman-Rubin Model of Causal Inference and Estimation via Matching Methods. In: Box-Steffensmeier J, Brady H, Collier D, eds. *The Oxford Handbook of Political Methodology*. Oxford: Oxford University Press; 2009.

2. Bang H, Robins JM. Doubly robust estimation in missing data and causal inference models. *Biometrics*. 2005;61:962–973. doi: 10.1111/j.1541-0420.2005.00377.x

3. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. *Epidemiology*. 2000;11:561–570. doi: 10.1097/00001648-200009000-00012

4. Rubin DB. *Matched Sampling for Causal Effects*. Cambridge: Cambridge University Press; 2006.

5. Brookhart MA, Wyss R, Layton JB, Stürmer T. Propensity score methods for confounding control in nonexperimental research. *Circ Cardiovasc Qual Outcomes*. 2013;6:604–611. doi: 10.1161/CIRCOUTCOMES.113.000359

6. Rosenbaum PR. *Observational studies*. 2nd ed. New York: Springer; 2002.

7. Williamson EJ, Forbes A, Wolfe R. Doubly robust estimators of causal exposure effects with missing data in the outcome, exposure or a confounder. *Stat Med*. 2012;31:4382–4400. doi: 10.1002/sim.5643

8. Li L, Shen C, Li X, Robins JM. On weighting approaches for missing data. *Stat Methods Med Res*. 2013;22:14–30. doi: 10.1177/0962280211403597

9. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. *Stat Med*. 2004;23:2937–2960. doi: 10.1002/sim.1903

10. Shen C, Li X, Li L. Inverse probability weighting for covariate adjustment in randomized studies. *Stat Med*. 2014;33:555–568. doi: 10.1002/sim.5969

11. Robins J, Rotnitzky A, Zhao LP. Estimation of regression coefficients when some regressors are not always observed. *J Am Stat Assoc*. 1994;89:846–866.

12. Funk M, Westeich D, Davidian M, Weisen C. Introducing a SAS® macro for doubly robust estimation. 2007. <https://www.med.unc.edu/pediatrics/research/harryguess/sas-macro-for-doubly-robust-estimation>.
13. Kereiakes DJ, Obenchain RL, Barber BL, Smith A, McDonald M, Broderick TM, Runyon JP, Shimshak TM, Schneider JF, Hattemer CR, Roth EM, Whang DD, Cocks D, Abbottsmith CW. Abciximab provides cost-effective survival advantage in high-volume interventional practice. *Am Heart J*. 2000;140:603–610. doi: 10.1067/mhj.2000.109647
14. Obenchain B. USPS: Unsupervised and Supervised methods of Propensity Score Adjustment for Bias. R package version 1.2-2. 2012. <https://CRAN.R-project.org/package=USPS>.
15. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. *Stat Med*. 2015;34:3661–3679. doi: 10.1002/sim.6607
16. Ho D, Imai K, King G, Stuart EA. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. *Polit Anal*. 2007;15:199–236.